Adoptive Cell Therapies
To Cure Patients
CARLA Biotherapeutics develops cell-based immunotherapies
to treat a broad range of diseases with a first focus in
hematological malignacies and solid tumors
CARLA Biotherapeutics is a spin-off of Franche-Comté University (UMR Right)
INSERM and French Blood Establishment (EFS)
CARLA Biotherapeutics is part of the Landmark Bioventures nexus of start-ups Biotechs
Pipeline
Co-founders and Directors
Zaki Sellam
MBA, Msc
Co-Founder
& President
• 20+ years of experience in Biotech
• Expert in Immuno-Oncology Drug Development
• Created and developed several start-ups & signed more than 40 Deals
Francine Garnache
MD, PhD
Co-Founder
& Board Member
-
30 years + experience in Hematology & Immunotherapy
-
MD PhD
-
Expert in CD123+ hemato-oncology
One patent and 60 publications
Fanny Delettre
Pharma D
Co-Founder
& Board Member
-
20 years+ Immuno-Hematology and Evaluation of cell therapies
-
PhD Pharm.D.
-
Director of EFS Besançon – Expert in Cell Therapy Production GMP Grade
Mehdi Chelbi
Msc
Co-Founder
& Board Member
-
20+ years of experience in in Biotech, Pharma and CROs
-
Entrepreneur and C-Level positions
-
Corporate development and fundraising
Olivier Adotevi
MD, PhD
Co-Founder
& Board Member
-
30 years+ experience clinical and translation research in Immunology & Oncology
-
MD PhD
-
Director of the UMR Right
-
Led multiple clinical programs dedicated to IO and anticancer immunotherapies
Operations
Maxime Fredon
Lead Scientist
R&D Project Manager
-
Solid experience in research and development of adaptive cell therapies
-
PhD in Immunology & CAR-T Cell in oncology
Elodie Bole Richard
Acting as Research & Bioproduction
Engineer
-
10+ years of experience in cell therapy development and production
-
Lead the EFS Bioproduction platform
Ecosystem & Partners
